Advertisement

Spencer Pharmaceutical Inc., a Boston drug development firm focused on metabolic disease treatments, has formed an agreement with National Pharmaceutical Corp. to co-develop treatments for Alzheimer’s and Parkinson’s disease.

According to terms of the agreement, the two companies will use a drug delivery platform developed by Spencer to create central nervous disease therapeutics.

SOURCE

Advertisement
Advertisement